家庭NB-UVB光疗治疗银屑病疗效不逊诊室光疗但使用不足

News|Articles|September 28, 2026

Listen

0:00 / 0:00

Key Takeaways

Pragmatic randomized data show home NB-UVB with guided dosimetry is noninferior to office phototherapy for PGA and DLQI outcomes across all skin phototypes.
Adherence markedly favors home treatment (51.4% vs 15.9%), supporting real-world effectiveness and reducing indirect patient burden relative to frequent in-office visits.
Persistent erythema is more common with home use (5.9% vs 1.2% of treatments), underscoring the value of protocolized dosing and patient education.
Long-term safety uncertainties include cumulative UV dose tracking and skin cancer risk over years of device use, representing a key evidentiary gap for coverage.
Implementation barriers may worsen inequities and are compounded by uncharacterized safety risks from OTC phototherapy devices lacking trial-like dosimetry oversight.

Home NB-UVB phototherapy matches office results, boosts psoriasis treatment adherence, and may improve access, but long-term safety, equity, and oversight lag.

A light box in a patient's own home clears psoriasis about as well as a course of standing appointments at a dermatology office, and patients adhere to it more than 3 times as often. A narrative review of 12 studies argues that home narrowband ultraviolet-B (NB-UVB) remains underused and names 3 gaps holding it back.¹

What the LITE Trial Established

The evidence anchor is the Light Treatment Effectiveness trial, an investigator-initiated pragmatic noninferiority study embedded in routine care at 42 US dermatology practices. It randomized 783 patients aged 12 years and older with plaque or guttate psoriasis to a home NB-UVB machine with guided dosimetry or to office-based NB-UVB for 12 weeks. Mean age was 48.0 years, 48.0% were female, and skin phototypes were deliberately balanced, with 44.7% types I/II, 44.7% types III/IV, and 10.6% types V/VI.²

At week 12, 32.8% of the home group and 25.6% of the office group reached clear or almost clear skin on the Physician Global Assessment, and 52.4% vs 33.6% reached a Dermatology Life Quality Index of 5 or lower. Home treatment was noninferior on both coprimary outcomes in the overall population and across every skin phototype, a point that matters because earlier phototherapy data in patients with darker skin were thin. Adherence separated the arms most sharply, at 51.4% versus 15.9% (P < .001), alongside lower indirect costs to patients.

A Narrative Synthesis, Not a Systematic One

The review searched PubMed and Embase for studies published between January 2020 and March 2026, yielding 12 included studies spanning randomized trials, observational work, cost analyses, implementation reports, and technical device comparisons. Findings were interpreted by study design without a formal risk-of-bias assessment, which the authors state plainly.¹

That design places this review below the systematic reviews and meta-analyses that typically anchor treatment coverage, and its conclusions inherit the strength of the underlying trials rather than adding independent weight. Its contribution is implementation guidance rather than new efficacy evidence, and it should be read that way.

Three Gaps Between Evidence and Practice

Erythema was the most common adverse event across the included studies and rarely led to discontinuation, but it did not fall evenly on the 2 arms. LITE recorded persistent erythema after 5.9% of home treatments against 1.2% of office treatments (P < .001), the one outcome on which supervised care came out ahead. Long-term safety data also remain limited, and the first gap the review identifies is the absence of cumulative UV exposure and skin cancer data over the years a home device might realistically be used, which is precisely the horizon a payer underwriting the equipment would care about.

The second is equity. The review argues that implementation barriers may paradoxically restrict access for the patients who stand to gain most, those for whom repeated office visits are hardest to make. The third is regulatory: over-the-counter phototherapy devices are reaching patients carrying safety risks the review describes as uncharacterized, a different proposition from the dosimetry-guided units issued under the trial protocol. Closing all 3 gaps, the authors argue, requires prospective safety studies, equity-centered implementation, and regulatory oversight before home phototherapy can be a widely accessible standard of care.

What It Means for Coverage

Home phototherapy occupies an unusual position in the psoriasis treatment landscape: an option with randomized evidence of noninferiority, better adherence, and lower patient cost that nonetheless sits behind systemic agents in practice. The review frames that as an implementation failure rather than an evidence failure.

The coverage case rests on a capital purchase displacing a recurring visit, a favorable structure provided the long-term safety question gets answered. Selection criteria are already clear enough to act on in plaque or guttate disease, and the device-quality gap argues for prescribing a guided-dosimetry unit rather than leaving patients to buy whatever is sold online.

References

1. Ghanim D, Thomas LE, Kim D, et al. Home phototherapy for psoriasis: evidence and implementation. Photodermatol Photoimmunol Photomed. 2026;42(5):e70117. doi:10.1111/phpp.70117

2. Gelfand JM, Armstrong AW, Lim HW, et al. Home- vs office-based narrowband UV-B phototherapy for patients with psoriasis: the LITE randomized clinical trial. JAMA Dermatol. 2024;160(12):1320-1328. doi:10.1001/jamadermatol.2024.3897